Search Results - "MELICHAR, B." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

by Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., Dhaene, K., Wiechen, K., Huber, C., Maurus, D., Arozullah, A., Park, J.W., Schuler, M., Al-Batran, S.-E.
Published in Annals of oncology (01.05.2021)

Get full text

Journal Article

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

by Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C.D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.
Published in Annals of oncology (01.06.2015)

Get full text

Journal Article

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study

by Poprach, A., Pavlik, T., Melichar, B., Puzanov, I., Dusek, L., Bortlicek, Z., Vyzula, R., Abrahamova, J., Buchler, T.
Published in Annals of oncology (01.12.2012)

Get full text

Journal Article

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

by Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B.L., Elliott, R., Weber, H.A., Ismael, G.
Published in Annals of oncology (01.02.2015)

Get full text

Journal Article

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

by Fuchs, C.S., Azevedo, S., Okusaka, T., Van Laethem, J.-L., Lipton, L.R., Riess, H., Szczylik, C., Moore, M.J., Peeters, M., Bodoky, G., Ikeda, M., Melichar, B., Nemecek, R., Ohkawa, S., Świeboda-Sadlej, A., Tjulandin, S.A., Van Cutsem, E., Loberg, R., Haddad, V., Gansert, J.L., Bach, B.A., Carrato, A.
Published in Annals of oncology (01.05.2015)

Get full text

Journal Article

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

by Rini, B.I., Melichar, B., Fishman, M.N., Oya, M., Pithavala, Y.K., Chen, Y., Bair, A.H., Grünwald, V.
Published in Annals of oncology (01.07.2015)

Get full text

Journal Article

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

by Élez, E., Kocáková, I., Höhler, T., Martens, U.M., Bokemeyer, C., Van Cutsem, E., Melichar, B., Smakal, M., Csőszi, T., Topuzov, E., Orlova, R., Tjulandin, S., Rivera, F., Straub, J., Bruns, R., Quaratino, S., Tabernero, J.
Published in Annals of oncology (01.01.2015)

Get full text

Journal Article

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry

by Buchler, T., Klapka, R., Melichar, B., Brabec, P., Dušek, L., Vyzula, R., Abrahamova, J.
Published in Annals of oncology (01.02.2012)

Get full text

Journal Article

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

by Ravaud, A., Barrios, C.H., Alekseev, B., Tay, M.-H., Agarwala, S.S., Yalcin, S., Lin, C.-C., Roman, L., Shkolnik, M., Anak, O., Gogov, S., Pelov, D., Louveau, A.-L., Melichar, B.
Published in Annals of oncology (01.07.2015)

Get full text

Journal Article

Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors

Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors

by Pastvova, N., Havlasek, J., Dolezel, P., Kikalova, K., Studentova, H., Zemankova, A., Melichar, B., Mlejnek, P.
Published in Cancer chemotherapy and pharmacology (01.07.2021)

Get full text

Journal Article

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

by Adiwijaya, BS, Kim, J, Lang, I, Csõszi, T, Cubillo, A, Chen, J‐S, Wong, M, Park, JO, Kim, JS, Rau, KM, Melichar, B, Gallego, JB, Fitzgerald, J, Belanger, B, Molnar, I, Ma, WW
Published in Clinical pharmacology and therapeutics (01.12.2017)

Get full text

Journal Article

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

by Evans, T.R.J., Van Cutsem, E., Moore, M.J., Bazin, I.S., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., O’Dwyer, P.J.
Published in Annals of oncology (01.02.2017)

Get full text

Journal Article

Correction to: Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors

Correction to: Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors

by Pastvova, N., Havlasek, J., Dolezel, P., Kikalova, K., Studentova, H., Zemankova, A., Melichar, B., Mlejnek, P.
Published in Cancer chemotherapy and pharmacology (01.10.2021)

Get full text

Journal Article

Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS)

Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS)

by Finek, J., Demlova, R., Kopeckova, K., Buchler, T., Melichar, B., Prausova, J., Poprach, A., Hrnciarova, T., Mlcoch, T., Dolezal, T.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers

Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers

by Van Cutsem, E., Melichar, B., Van den Eynde, M., Prausova, J., Geboes, K., Dekervel, J., Vitaskova, D., De Cuyper, A., Linke, Z., Van Acker, N., Frenois, F., Noel, G., Prost, J., Barret, J., Jean, B., Tabah-Fisch, I.
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer

Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer

by Gatek, J, Petru, V, Kosac, P, Ratajsky, M, Duben, J, Dudesek, B, Jancik, P, Zabojnikova, M, Katrusak, J, Opelova, P, Podrazska, L, Vazan, P, Kudlova, P, Holik, P, Melichar, B, Vrana, D
Published in Neoplasma (01.11.2020)

Get more information

Journal Article

The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type

The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type

by Dvorak, J., Rosova, B., Filipova, A., Hadzi Nikolov, D., Dusek, L., Rozsypalova, A., Proks, J., Richter, I., Melichar, B., Buchler, T., Zachoval, R., Matej, R.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Regorafenib for metastatic colorectal carcinoma: A registry-based analysis

Regorafenib for metastatic colorectal carcinoma: A registry-based analysis

by Kopeckova, K, Chloupkova, R, Melichar, B, Linke, Z, Petruzelka, L B, Finek, J, Fiala, O, Tomasek, J, Kiss, I, Prausova, J, Buchler, T
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

by Buchler, T, Fiala, O, Veskrnova, V, Chloupkova, R, Poprach, A, Kiss, I, Kopeckova, K, Dusek, L, Slavicek, L, Kohoutek, M, Finek, J, Svoboda, M, Dvorak, J, Petruzelka, L B, Melichar, B
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

by Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C
Published in British journal of cancer (25.11.2014)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[17]